Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Cash & Current Investments (2024 - 2025)

Kairos Pharma's Cash & Current Investments history spans 2 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments changed N/A year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, changed N/A, while the annual FY2025 figure was $4.5 million, N/A changed from the prior year.
  • Cash & Current Investments reached $4.5 million in Q4 2025 per KAPA's latest filing, up from $3.0 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $4.5 million in Q4 2025 to a low of $3.0 million in Q2 2025.